Induced Pluripotent Stem Cell Therapies in Poland from a Public Health Perspective: Regulatory Deficit and the Untapped Potential of Pharmacists

Iwona Wrześniewska-Wal

doi:10.21697/ejhp.0112.01

Opublikowane: 2026-06-30

Tom 6 Nr 1 (2026)

Terapie z wykorzystaniem indukowanych pluripotencjalnych komórek macierzystych w Polsce z perspektywy zdrowia publicznego: braki regulacyjne i niewykorzystany potencjał farmaceutów

Iwona Wrześniewska-Wal

European Journal of Health Policy, Humanization of Care and Medical Ethics

Dział: Articles

https://doi.org/10.21697/ejhp.0112.01

Abstrakt

A substantial part of this study consists of an analysis of the legal framework governing advanced therapy medicinal products (ATMPs), including the hospital exemption mechanism. The author highlights the lack of uniformity in the regulatory framework across the European Union and the differences in the approaches adopted by jurisdictions such as the United States, Japan and Switzerland. The aim of the paper is to evaluate Polish regulations against the international background and to identify possible directions for their further development, particularly in the context of planned legislative changes and the potential role of the pharmacist within the system.

Słowa kluczowe:

indukowane pluripotencjalne komórki macierzyste, produkty lecznicze stosowane w terapii zaawansowanej

Pobierz pliki

pdf (English)

Cited by / Share

Licencja

Bibliografia

Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Act No. 145 of 1960). (1960). Retrieved March 30, 2026 from https://www.japaneselawtranslation.go.jp/en/laws/view/3213/en
Google Scholar

Act on the Safety of Regenerative Medicine (Act No. 85 of 2013, as amended by Act No. 68 of 2022).(2022). Retrieved March 30, 2026 from https://www.japaneselawtranslation.go.jp/en/laws/view/4980/en
Google Scholar

Bobis-Wazowicz, S. (2025, July 13). Induced pluripotent stem cells (iPSCs): Practical guide and application possibilities [Training material]. Tygiel Foundation.
Google Scholar

Carpenter, M. K . (2017). Regulatory considerations for pluripotent stem cell therapies. In S . B . Dunnett & A. Björklund (Eds), Progress in Brain Research: Vol. 230. Functional Neural Transplantation IV (pp. 151–163). Elsevier. doi:10.1016/bs.pbr.2016.12.008. DOI: https://doi.org/10.1016/bs.pbr.2016.12.008
Google Scholar

Code of F ederal Regulations. (n.d.). Title 21, Part 1271. Retrieved March 30, 2026 from https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271
Google Scholar

Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. (2001). Off J Eur Communities. L311:67–128.
Google Scholar

Directive of the European Parliament and of the Council on the Union code relating to medicinal products for human use, and repealing Directive 2001/83/EC and Directive 2009/35/EC. COM(2023)192 final. (2023).
Google Scholar

Herberts, C. A ., Kwa, M. S ., & Hermsen, H. P. (2011). Risk factors in the development of stem cell therapy. J Transl Med, 9(29). doi:10.1186/1479-5876-9-29 DOI: https://doi.org/10.1186/1479-5876-9-29
Google Scholar

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). Retrieved March 30, 2026 from https://www.ich.org/
Google Scholar

Lin, H. T ., Otsu, M., & Nakauchi, H. (2013). Stem cell therapy: An exercise in patience and prudence. Philos Trans R Soc Lond B Biol Sci, 368(1609), 20110334. doi:10.1098/rstb.2011.0334 DOI: https://doi.org/10.1098/rstb.2011.0334
Google Scholar

Marei, H. E. (2025). Stem cell therapy: Revolutionary cure or Pandora’s box? Stem Cell Res Ther, 16(255). doi:10.1186/s13287-025-04334-1 DOI: https://doi.org/10.1186/s13287-025-04334-1
Google Scholar

Pharmaceutical Law Act of 6 September 2001 (Journal of L aws of the Republic of Poland, 2001, No. 126, item 1381, as amended). (2001).
Google Scholar

Pecyna, M. (2024). Use of advanced therapy medicinal products – Hospital exemption and therapeutic experiment. Diametros, 81(66–79). doi:10.33392/diam.1930 DOI: https://doi.org/10.33392/diam.1930
Google Scholar

Pecyna, M. & Dulak, J. (2022). The concept of advanced therapy medicinal products – Hospital exemption in EU law and Polish regulation based on stem cell therapies. Eur Rev Judic, 11, 12–20.
Google Scholar

Public Health Service Act, Title III. A s amended through P.L. 119–75, enacted February 3, 2026. Washington (DC): Office of the Law Revision Counsel. (2026). Retrieved March 29, 2026 from https://www.govinfo.gov/app/collection/comps/
Google Scholar

Reis, R. L . (Ed.). (2019). Regulatory approaches and marketing approvals: A comparison of three systems. In Encyclopedia of Tissue Engineering and Regenerative Medicine (pp. 167–206). doi:10.1016/B978-0-12-801238-3.65578-2 DOI: https://doi.org/10.1016/B978-0-12-801238-3.65578-2
Google Scholar

Regulation (EC) No. 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No. 726/2004. Off J Eur Union. L324:121–137.
Google Scholar

Regulation of the Minister of H ealth of 5 February 2019 on the template application for authorisation to manufacture an advanced therapy medicinal product – hospital exemption and for amendmentof such authorisation. (2019). Journal of Laws of the Republic of Poland, 2019, item 313).
Google Scholar

Sipp, D. (2011). Global update: Japan. Regen Med, 6(6 Suppl.), 160–162. doi:10.2217/rme.11.65 DOI: https://doi.org/10.2217/rme.11.65
Google Scholar

Sobhani, A., Khanlarkhani, N., Baazm, M., Mohammadzadeh, F., Najafi, A., Mehdinejadiani, S., Sargolzaei Aval, F. (2017). Multipotent stem cell and current application. Acta Med Iran, 55(1), 6–23.
Google Scholar

Therapeutic Products Act of 15 December 2000 (SR 812.21). (2000). Retrieved March 29, 2026 from https://www.fedlex.admin.ch/eli/cc/2001/422/en
Google Scholar

Wrześniewska-Wal, I. (2015). Regenerative medicine for athletes: Legal and ethical aspects. In T . Gardocka & D. Jagiełło (Eds), Legal issues at the intersection of sport and medicine (pp. 139–149).
Google Scholar

Wrześniewska-Wal, I. (2016). Use of stem cells in medicine: Legal and ethical aspects. In P. S zczepańczyk (Ed.), Bioethics (pp. 7–24). UNITAS Publishing House of the Diocese of Siedlce.
Google Scholar

Wrześniewska-Wal, I. (2025). Between law and practice: Poland’s regulatory deficit in iPSC therapies and the pharmacist’s untapped potential [Poster; 6th Central European Biomedical Congress “Integrating Neuropharmacology and Bioinformatics with AI”, July 22–24, 2025, Krakow, Poland].
Google Scholar